Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


12>>>
29 Items
Title  Creator  Group name  Publishing year 
[Immunotherapy in urology: Concept and results] Pignot and Houede EquipeCG Aug 30, 2019
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1 Smith et al. EquipeCG Jul 11 2016
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post hoc Analysis of the Mainsail Study de Morree et al. EquipeCG Aug 25 2016
Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort Pouessel et al. EquipeCG Jul 21 2016
[Tasquinimod: How to act on microenvironment in metastatic prostate cancer] Houede and Irani EquipeCG May 2015
[Professional's expectations to improve quality of care and social services utilization in geriatric oncology] Antoine et al. EquipeCG Feb 2015
Prostate cancer incidence on cystoprostatectomy specimens is directly linked to age: results from a multicentre study Pignot et al. EquipeCG Jan 2015
Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial Blanchard et al. EquipeCG Sep 25 2015
Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma Houede et al. EquipeCG Jan 20 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN projectdagger Kramar et al. EquipeCG Sep 14 2015
Formal consensus method to evaluate the conformity of prescription of a recently approved chemotherapy treatment in an observatory study Houede et al. EquipeCG 2015
Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients Roubaud et al. EquipeCG 2015
Dynamic contrast enhanced MRI-derived parameters are potential biomarkers of therapeutic response in bladder carcinoma Chakiba et al. EquipeCG Jun 2015
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial Petrylak et al. EquipeCG Apr 2015
Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old Comperat et al. EquipeCG May 2015
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study Joly et al. EquipeCG Jan 2015
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial Fizazi et al. EquipeCG May 28 2015
Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France Houede et al. EquipeCG 2015
[Non-surgical treatment modalities available for the treatment of upper tract urothelial carcinomas: state-of-the-art for the yearly scientific report of the French National Association of Urology] Audenet et al. EquipeCG Nov 2014
Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: Its potential use in the treatment of bladder cancers Houede and Pourquier EquipePM Jun 11 2014
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer Michaelson et al. EquipeCG Jan 10 2014
Nutritional advice in older patients at risk of malnutrition during treatment for chemotherapy: a two-year randomized controlled trial Bourdel-Marchasson et al. EquipeCG 2014
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial Kwon et al. EquipeCG Jun 2014
Hemorrhagic cystitis in patients treated with cabazitaxel: a radiation recall syndrome? Grellety et al. EquipeCG Jun 2014
Dyadic effects of coping strategies on emotional state and quality of life in prostate cancer patients and their spouses Lafaye et al. EquipeCG Jul 2014
12>>>
29 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés